CanBas Co., Ltd. Share · JP3244570002 (XTKS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of CanBas Co., Ltd.

No Price

Closing Price XTKS 01.05.2026: 679,00 JPY

01.05.2026 05:37

Current Prices from CanBas Co., Ltd.

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
Tokyo	4575.T	JPY	01.05.2026 05:37	679,00 JPY	14,00 JPY +2,11 %

Share Float & Liquidity

Free Float 96,44 %

Shares Float 19 M

Shares Outstanding 19,7 M

Company Profile for CanBas Co., Ltd. Share

CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.

Company Data

Name CanBas Co., Ltd.

Company CanBas Co., Ltd.

Website https://www.canbas.co.jp

Primary Exchange

Tokyo

ISIN JP3244570002

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Takumi Kawabe

Market Capitalization 13 Mrd.

Country Japan

Currency JPY

Employees 0,0 T

Address 2-2-1, Otemachi, 410-0801 Numazu

IPO Date 2009-09-17

Ticker Symbols

Name	Symbol
Tokyo	4575.T

More Shares

Investors who hold CanBas Co., Ltd. also have the following shares in their portfolio:

AIS-AM.FL.RA.EO.C.ESGHLSC ETF

GREVENB.4 ANL.20/23 Bond